Madrigal Pharmaceuticals (MDGL) Competitors $437.10 +9.37 (+2.19%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$437.66 +0.56 (+0.13%) As of 10/14/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MDGL vs. BIIB, UTHR, INCY, NBIX, IONS, EXEL, EXAS, BMRN, RGEN, and HALOShould you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL), Exact Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. Madrigal Pharmaceuticals vs. Its Competitors Biogen United Therapeutics Incyte Neurocrine Biosciences Ionis Pharmaceuticals Exelixis Exact Sciences BioMarin Pharmaceutical Repligen Halozyme Therapeutics Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability. Which has more volatility and risk, BIIB or MDGL? Biogen has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.02, suggesting that its stock price is 202% less volatile than the S&P 500. Does the media refer more to BIIB or MDGL? In the previous week, Biogen had 30 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 39 mentions for Biogen and 9 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.83 beat Biogen's score of 0.54 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 13 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of BIIB or MDGL? 87.9% of Biogen shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is BIIB or MDGL more profitable? Biogen has a net margin of 15.31% compared to Madrigal Pharmaceuticals' net margin of -54.68%. Biogen's return on equity of 13.85% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Madrigal Pharmaceuticals -54.68%-38.38%-27.32% Which has higher valuation and earnings, BIIB or MDGL? Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.20$1.63B$10.4613.89Madrigal Pharmaceuticals$180.13M53.87-$465.89M-$12.85-34.02 Do analysts rate BIIB or MDGL? Biogen currently has a consensus price target of $180.69, suggesting a potential upside of 24.35%. Madrigal Pharmaceuticals has a consensus price target of $531.89, suggesting a potential upside of 21.69%. Given Biogen's higher possible upside, equities research analysts plainly believe Biogen is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 1 Sell rating(s) 19 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.32Madrigal Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 SummaryBiogen beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDGL vs. The Competition Export to ExcelMetricMadrigal PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.50B$2.64B$6.05B$10.52BDividend YieldN/A57.77%5.73%4.79%P/E Ratio-34.0222.5685.0427.24Price / Sales53.87699.21588.28231.77Price / CashN/A174.0137.5761.53Price / Book12.645.3612.676.74Net Income-$465.89M$33.06M$3.32B$276.59M7 Day Performance0.03%-1.31%-1.35%-0.47%1 Month Performance2.70%11.42%8.09%7.47%1 Year Performance102.20%-1.34%78.89%34.58% Madrigal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDGLMadrigal Pharmaceuticals4.377 of 5 stars$437.10+2.2%$531.89+21.7%+102.9%$9.50B$180.13M-34.0290Analyst ForecastBIIBBiogen4.6708 of 5 stars$154.05-3.6%$180.04+16.9%-24.1%$23.44B$9.68B14.737,605Analyst ForecastAnalyst RevisionUTHRUnited Therapeutics4.3904 of 5 stars$453.28+0.0%$449.57-0.8%+21.4%$20.44B$2.88B17.691,305INCYIncyte4.3937 of 5 stars$87.23+0.4%$83.64-4.1%+31.4%$16.96B$4.24B19.832,617NBIXNeurocrine Biosciences4.8292 of 5 stars$139.43+1.8%$161.89+16.1%+17.9%$13.59B$2.36B41.251,800IONSIonis Pharmaceuticals3.4181 of 5 stars$69.02-0.2%$75.29+9.1%+84.8%$11.02B$705M-37.511,069EXELExelixis4.771 of 5 stars$40.01-0.2%$44.42+11.0%+50.6%$10.79B$2.17B19.241,147Analyst RevisionEXASExact Sciences4.3257 of 5 stars$57.63+1.6%$68.52+18.9%-14.6%$10.74B$2.94B-10.617,000BMRNBioMarin Pharmaceutical4.9346 of 5 stars$55.61+0.3%$92.95+67.1%-25.3%$10.64B$2.85B16.503,040Positive NewsAnalyst RevisionRGENRepligen4.5013 of 5 stars$150.10+0.9%$168.08+12.0%+3.7%$8.37B$634.44M-600.381,778HALOHalozyme Therapeutics4.7756 of 5 stars$66.97-2.9%$70.44+5.2%+23.5%$8.07B$1.02B15.32390Analyst Upgrade Related Companies and Tools Related Companies Biogen Competitors United Therapeutics Competitors Incyte Competitors Neurocrine Biosciences Competitors Ionis Pharmaceuticals Competitors Exelixis Competitors Exact Sciences Competitors BioMarin Pharmaceutical Competitors Repligen Competitors Halozyme Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDGL) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
